Pancreatic Cancer Research

ResearcherSun Yat-sen UniversityActive in the last 2 years

Xin Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6036-2685; OpenAlex author ID A5110516399. Sources: OpenAlex.

Their work

Papers
11
Trials
0
Grants
0
Labs led
0
Collaborators
37
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: 1 paper · 2019: none · 2020: 2 papers · 2021: none · 2022: 2 papers · 2023: 1 paper · 2024: 2 papers · 2025: 1 paper · 2026: 1 paper

Papers 11

  1. The 30% reduction of baseline CA19-9 could stratify the prognosis of advanced pancreatic ductal adenocarcinoma with RECIST stable disease after first-line chem… Co-author DOI 10.1186/s12885-026-16353-z↗
  2. ITGB5-mediated biomechanical regulation in pancreatic ductal adenocarcinoma stroma impacts tumor progression and prognosis. Co-author DOI 10.1186/s12967-025-07119-5↗
  3. B3GNT5 is a novel marker correlated with malignant phenotype and poor outcome in pancreatic cancer. Co-author DOI 10.1016/j.isci.2024.110889↗
  4. Influence of myosteatosis on survival of patients with pancreatic cancer: A systematic review and meta-analysis. Co-author DOI 10.1016/j.isci.2024.111343↗
  5. Xanthoxyletin blocks the RANK/RANKL signaling pathway to suppress the growth of human pancreatic cancer cells. Co-author DOI 10.2478/acph-2023-0024↗
  6. Progranulin mediates immune evasion of pancreatic ductal adenocarcinoma through regulation of MHCI expression. Co-author DOI 10.1038/s41467-021-27088-9↗
  7. High‑glucose microenvironment promotes perineural invasion of pancreatic cancer via activation of hypoxia inducible factor 1α. Co-author DOI 10.3892/or.2022.8275↗
  8. Characterization of a dual BET/HDAC inhibitor for treatment of pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.33137↗
  9. FAM84B, amplified in pancreatic ductal adenocarcinoma, promotes tumorigenesis through the Wnt/β-catenin pathway. Co-author DOI 10.18632/aging.103044↗
  10. miR-1266 Contributes to Pancreatic Cancer Progression and Chemoresistance by the STAT3 and NF-κB Signaling Pathways. Co-author DOI 10.1016/j.omtn.2018.01.004↗
  11. Notch4 inhibition reduces migration and invasion and enhances sensitivity to docetaxel by inhibiting Akt/fascin in pancreatic cancer cells. Co-author DOI 10.3892/ol.2016.5097↗

Closest collaborators

The 25 strongest of 37 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Chen‐Song Huang · 1 shared paper, 2026 · strength 0.32
  2. Xiaoyu Yin · 1 shared paper, 2026 · strength 0.32
  3. Xi‐Tai Huang · 1 shared paper, 2026 · strength 0.32
  4. Wei Yao · 1 shared paper, 2024 · strength 0.31
  5. Yuhe Lin · 1 shared paper, 2024 · strength 0.31
  6. Yan Wu · 1 shared paper, 2023 · strength 0.31
  7. Xing Li · 1 shared paper, 2024 · strength 0.24
  8. Feng Gao · 1 shared paper, 2025 · strength 0.22
  9. Yu Shi · 1 shared paper, 2025 · strength 0.22
  10. Aoran Yang · 1 shared paper, 2025 · strength 0.22
  11. Sven‐Thorsten Liffers · 2 shared papers, 2020–2022 · strength 0.19
  12. Phyllis F. Cheung · 2 shared papers, 2020–2022 · strength 0.19
  13. Jens Thomas Siveke · 2 shared papers, 2020–2022 · strength 0.19
  14. Weili Min · 1 shared paper, 2022 · strength 0.16
  15. Wunai Zhang · 1 shared paper, 2022 · strength 0.16
  16. Wěi Li · 1 shared paper, 2022 · strength 0.16
  17. Lun Zhang · 1 shared paper, 2022 · strength 0.16
  18. Ronglin Yan · 1 shared paper, 2020 · strength 0.11
  19. Qingping Cai · 1 shared paper, 2020 · strength 0.11
  20. Dejun Yang · 1 shared paper, 2020 · strength 0.11
  21. Marcus Bahra · 1 shared paper, 2022 · strength 0.10
  22. Rui Fang · 1 shared paper, 2022 · strength 0.10
  23. Jana Käthe Striefler · 1 shared paper, 2022 · strength 0.10
  24. Erik H.J.G. Aarntzen · 1 shared paper, 2022 · strength 0.10
  25. Marianne Sinn · 1 shared paper, 2022 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.